Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials

被引:0
|
作者
Lezo Ramirez, Daisy [1 ]
Koleske, Emily [1 ]
Ometoruwa, Omolola [1 ]
Park Chang, Jun Bai [1 ]
Kanwal, Urwah [1 ]
Morreale, Nicholas [1 ]
Avila Paz, Andres Alberto [1 ]
Tong, Alexandra [1 ]
Baden, Lindsey R. [1 ,2 ]
Sherman, Amy C. [1 ,2 ]
Walsh, Stephen R. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02130 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
关键词
clinical trial enrollment; diversity; representation; vaccine; HIV; SARS-CoV-2; HEALTH; MINORITIES; GENDER; SEX;
D O I
10.3389/fpubh.2024.1411970
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Vaccine clinical trials should strive to recruit a racially, socioeconomically, and ethnically diverse range of participants to ensure appropriate representation that matches population characteristics. Yet, full inclusion in research is often limited.Methods A single-center retrospective study was conducted of adults enrolled at Brigham and Women's Hospital (Boston, MA) between July 2020 and December 2021. Demographic characteristics, including age, race, ethnicity, ZIP code, and sex assigned at birth, were analyzed from both HIV and COVID-19 vaccine trials during the study period, acknowledging the limitations to representation under these parameters. We compared the educational attainment of vaccine trial participants to residents of the Massachusetts metropolitan area, geocoded participants' addresses to their census block group, and linked them to reported median household income levels from publicly available data for 2020. Frequency and quartile analyses were carried out, and spatial analyses were performed using ArcGIS Online web-based mapping software (Esri).Results A total of 1030 participants from four COVID-19 vaccine trials (n = 916 participants) and six HIV vaccine trials (n = 114 participants) were included in the analysis. The median age was 49 years (IQR 33-63) and 28 years (IQR 24-34) for the COVID-19 and HIV vaccine trials, respectively. Participants identifying as White were the majority group represented for both the COVID-19 (n = 598, 65.3%) and HIV vaccine trials (n = 83, 72.8%). Fewer than 25% of participants identified as Hispanic or Latin. Based on ZIP code of residence, the median household income for COVID-19 vaccine clinical trial participants (n = 846) was 102,088 USD (IQR = 81,442-126,094). For HIV vaccine clinical trial participants (n = 109), the median household income was 101,266 USD (IQR 75,052-108,832).Conclusion We described the characteristics of participants enrolled for HIV and COVID-19 vaccine trials at a single center and found similitude in geographical distribution, median incomes, and proportion of underrepresented individuals between the two types of vaccine candidate trials. Further outreach efforts are needed to ensure the inclusion of individuals from lower educational and socioeconomic brackets. In addition, continued and sustained efforts are necessary to ensure inclusion of individuals from diverse racial and ethnic backgrounds.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
    Mehrotra, Devan, V
    Janes, Holly E.
    Fleming, Thomas R.
    Annunziato, Paula W.
    Neuzil, Kathleen M.
    Carpp, Lindsay N.
    Benkeser, David
    Brown, Elizabeth R.
    Carone, Marco
    Cho, Iksung
    Donnell, Deborah
    Fay, Michael P.
    Fong, Youyi
    Han, Shu
    Hirsch, Ian
    Huang, Ying
    Huang, Yunda
    Hyrien, Ollivier
    Juraska, Michal
    Luedtke, Alex
    Nason, Martha
    Vandebosch, An
    Zhou, Honghong
    Cohen, Myron S.
    Corey, Lawrence
    Hartzel, Jonathan
    Follmann, Dean
    Gilbert, Peter B.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (02) : 221 - +
  • [2] Clinical Equipoise in COVID-19 Vaccine Candidate Trials
    Dal-Re, Rafael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (09): : 1249 - 1250
  • [3] Improving Diversity in COVID-19 Vaccine Clinical Trial Enrollment: A Retrospective Analysis
    Davis, A. J.
    Schnapp, L. M.
    Bidar-Sielaff, S.
    Siraj, D. S.
    Henderson, S. L.
    Zapata, J. Y.
    Osman, F.
    Veintimilla, R. F.
    Elizabeth, N. W.
    Hartman, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] Clinical trials of COVID-19 vaccine development: a global overview
    Lopes, Joao Victor Antunes
    de Campos, Andre Luiz Sica
    de Moraes, Rafael Rodrigues
    Alves, Luciana Correia
    CADERNOS DE SAUDE PUBLICA, 2023, 39 (05):
  • [5] Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials
    Joffe, Steven
    Babiker, Abdel
    Ellenberg, Susan S.
    Fix, Alan
    Griffin, Marie R.
    Hunsberger, Sally
    Kalil, Jorge
    Levine, Myron M.
    Makgoba, Malegapuru W.
    Moore, Renee H.
    Tsiatis, Anastasios A.
    Whitley, Richard
    JOURNAL OF INFECTIOUS DISEASES, 2021, 224 (12): : 1995 - 2000
  • [6] Preparatory phase for clinical trials of COVID-19 vaccine in Nepal
    Gupta, Govind Prasad
    Shah, Yogendra
    Pant, Dhan Kumar
    Lekhak, Sunil
    Shahi, Ramesh
    Mandal, Ananda
    Poudel, Pramod
    Dumre, Shayam Prakash
    Pandey, Kishor
    Pandey, Basu Dev
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 418 - 419
  • [7] COVID-19 vaccine trials in Africa
    Makoni, Munyaradzi
    LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : E79 - E80
  • [8] Enrollment of Pediatric Patients in COVID-19 Interventional Trials
    Ong, Mei-Sing
    Wu, Ann Chen
    Bourgeois, Florence T.
    JAMA HEALTH FORUM, 2023, 4 (11): : E233939
  • [9] Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials
    Unger, Joseph M.
    Blanke, Charles D.
    LeBlanc, Michael
    Hershman, Dawn L.
    JAMA NETWORK OPEN, 2020, 3 (06) : E2010651
  • [10] Examining reporting and representation of patients with cancer in COVID-19 clinical trials
    Rabow, Maya
    Wang, Christine
    Zhang, Sylvia
    Tahir, Peggy Mary
    Small, Eric J.
    Borno, Hala T.
    CANCER REPORTS, 2021, 4 (04)